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Glyceryl trinitrate (GTN), a nitric oxide donor, is a candidate treatment for the 
management of acute stroke with haemodynamic and potential reperfusion and 
neuroprotective effects.  
 
Areas covered 
Here we discuss the evidence to date from clinical trials and present and future 
possibilities for the clinical application of transdermal GTN in acute stroke. When 
administered as a transdermal patch during the acute and subacute phases after 
stroke, GTN was safe, lowered blood pressure, maintained cerebral blood flow, and 
did not induce cerebral steal or alter functional outcome. However, when given within 
the hyperacute phase (<6 hours of stroke onset), GTN reduced death and 
dependency, death, disability, cognitive impairment, and mood disturbance, and 
improved quality of life. However, in a large pre-hospital trial with treatment within 4 
hours, GTN did not influence clinical outcomes. 
 
Expert opinion 
Transdermal GTN is an easy to administer BP-lowering therapy, which is safe when 
given after 2 hours of stroke onset, may improve outcome when initiated within 2-6 
hours, but should be avoided (outside of a clinical trial) in the ultra-acute period 
within 2 hours of stroke onset. Further research needs to investigate the mechanisms 
of benefit or harm in ultra/hyperacute stroke patients. 
 
Article highlights 
• Transdermal glyceryl trinitrate (GTN) is safe when administered after 2 hours of 
stroke onset. 
• Transdermal GTN may improve outcome if administered 2-6 hours after stroke 
onset, but may cause harm if used earlier. 
• Further research is needed to investigate whether lowering BP in ultra-acute 




Nitric oxide (NO) is an obligate inorganic molecule in both human health and disease 
with anti-inflammatory, anti-leucocyte [1], anti-platelet [2,3], anti-proliferative 
(vascular smooth muscle cell) [4], neuroprotective, neurotransmitter, neuromodulator 
[5,6], pro-endothelial and vasodilatory properties. NO modulates blood brain barrier 
integrity, cerebral blood flow (CBF), auto- and chemo-regulation [7-9], and inhibits 
apoptosis [10]. Pre-clinical models of cerebral ischaemia have demonstrated the role 
of NO in a time-dependent manner. NO is synthesised from L-arginine by three forms 
of nitric oxide synthase (NOS) with differing resultant effects. NO production is 
increased via neuronal NOS (nNOS) activation for up to 30 minutes after middle 
cerebral artery (MCA) occlusion [11,12]. Endothelial NOS (eNOS) and nNOS activity 
increases in the first minutes following arterial occlusion and falls thereafter [13]. Up-
regulation of inducible NOS (iNOS) occurs from 12 hours up to 7 days after ischaemia 
onset [14], whilst NO within cerebral tissue is undetectable during this period [11]. 
Intravenous L-arginine administered to rats following MCA occlusion improved 
penumbral blood flow and reduced infarct volume [15]. This effect was not seen in 
eNOS-deficient mice who developed smaller penumbral regions, larger infarcts and 
absent angiogenesis leading to further post-ischaemic injury [16-18]. Therefore, 
eNOS and eNOS-derived NO appear to be cytoprotective in focal ischaemia, whilst 
nNOS- and iNOS-derived NO have damaging effects on tissue survival with resultant 
poor neurological outcomes [12,19]. Although neurotoxic in acute stroke, iNOS and 
nNOS are involved in neurogenesis following stroke [20,21]. NO donors reduced 
infarct size in both permanent and transient pre-clinical models of ischaemia, and 
increased cerebral blood flow in permanent models, but only if administered soon 
after stroke induction [22]. 
 
Blood pressure (BP) is elevated in 75% of people with acute stroke at presentation 
[23] and is associated with worse functional outcome and increased death in both 
ischaemic and haemorrhagic stroke [24,25], stroke recurrence in ischaemic stroke 
[26] and haematoma expansion or rebleeding in intracerebral haemorrhage (ICH) 
[27]. Lowering elevated BP in acute stroke has long been debated and investigated. 
Resultant trials have led to treatment of raised BP in ICH being recommended [28]. 
 
Due to the variety of potentially beneficial effects of NO described above and the low 
levels of endogenous NO in stroke [29,30], supplementation through administration of 
NO donors might be beneficial but remains unclear. In contrast, diaspirin cross-linked 
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haemoglobin lowers vascular NO levels [31] and was associated with poor 
neurological outcome in acute stroke. Therefore, lowering NO may worsen outcomes 
in acute stroke, whilst increasing NO may be beneficial [32]. Based on these pre-
clinical data, the NO donor glyceryl trinitrate (GTN) has been assessed in stroke 
patients. Of note, GTN does not have significant intravascular effects on leucocytes 
[33] and platelets. Transdermal delivery of GTN in stroke patients provides easy 
application and removal without the need for swallowing assessment or intravenous 
access. GTN patches are used in the management of hypertension and ischaemic 
heart disease with peak plasma concentrations reached in 1-2 hours of application[34] 
and rapid fall in plasma concentrations when removed [35]. Importantly, in 
comparison to sublingual administration, transdermal preparations are less likely to 
cause rapid and large falls in BP. Although intravenous GTN is used to lower BP in 
acute stroke, there is limited data on this route of administration. In contrast, 
transdermal GTN has been extensively investigated in stroke patients in ultra-acute 
(first few hours), hyper-acute (<6 hours), acute (6-48 hours) and subacute (>48 
hours) time periods from stroke onset. Here, we discuss the evidence to date and 
current and future potential clinical applications of transdermal GTN in acute stroke. 
 
2. Transdermal GTN and acute stroke 
Transdermal GTN has been assessed in acute and subacute stroke patients in three 
small phase II randomised studies. As well as lowering peripheral and central BP, GTN 
reduced 24 hour BP, peak systolic BP, pulse pressure and pulse pressure index. 
Although GTN marginally increased heart rate, it was associated with improved 
vascular compliance. GTN did not influence intracranial pressure, cerebral blood flow 
and velocity, or induce cerebral steal (Table 1) [36-40]. Intravenous sodium 
nitroprusside, another nitric oxide donor, has antiplatelet properties [41], whilst GTN 
did not influence platelet function in the GTN-1 trial [36]. The safety and efficacy of 
transdermal GTN were assessed in the large Efficacy of Nitric Oxide in Stroke (ENOS) 
trial [42]. 
 
Between 2001 and 2014 ENOS enrolled 4011 patients from 173 centres in 23 
countries worldwide with acute stroke within 48 hours of onset and systolic BP 140-
220 mmHg; participants were randomised to transdermal GTN patch (5 mg) or no 
patch daily for 7 days. Patches were sourced from a variety of manufacturers but no 
differences in safety or efficacy were noted. All participants received standard acute 
stroke care including stroke unit admission, thrombolysis and secondary prevention 
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where appropriate. GTN lowered BP by 7.0 / 3.5 mmHg compared to no GTN at day 1 
and administration was safe with no increased reporting of serious adverse events. 
The primary outcome of functional outcome was assessed by telephone at day 90 
using the modified Rankin Scale (mRS), a seven level scale ranging from zero = no 
symptoms, through increasing levels of dependency, to six = death. Overall, GTN did 
not influence functional outcome at day 90 (adjusted common odds ratio [acOR] 1.01, 
95% confidence intervals [CI] 0.91-1.13), nor any secondary outcomes [42]. 
However, in a pre-specified subgroup of participants randomised within six hours of 
stroke ictus (ENOS-early), those randomised to GTN had a favourable shift in mRS at 
day 90 (acOR 0.51, 95% CI 0.32-0.80), less death, disability (Barthel index) and 
mood disturbance (Zung depression scale), and improved cognition (telephone Mini-
Mental State Examination) and quality of life scores (EuroQol health utility status and 
visual analogue scale) [43]. Similarly, the small (n=41) ambulance-based Rapid 
Intervention with Glyceryl trinitrate in Hypertensive stroke Trial (RIGHT) found that 
transdermal 5 mg GTN administered within four hours of ictus improved mRS at day 
90 [44]. 
 
A 2017 Cochrane review and an individual patient data meta-analysis in 2016 using 
data from five completed transdermal GTN trials in acute stroke (GTN-1/2/3, ENOS, 
RIGHT, n=4197) re-iterated that treatment within six hours of stroke onset (n=312) 
was associated with improved functional outcome and secondary clinical outcomes 
across a range of domains, but beyond this GTN had a neutral effect[45,46]. These 
findings were based upon high-quality evidence as assessed by GRADE criteria [46]. 
This potential time-dependent treatment effect was seen in both ischaemic and 
haemorrhagic stroke. Those participants with ICH randomised to GTN within 6 hours 
of onset had significant improvements in functional outcome, cognition, disability, 
mood and quality of life at 90 days compared with those randomised to no GTN [47]. 
Additionally, GTN appeared to have an additive effect with alteplase in those patients 
with ischaemic stroke; these participants had a significant shift to less death and 
dependency [45]. 
 
The safety of transdermal GTN in acute stroke has also been assessed in important 
patient subgroups. Although there is concern that BP lowering may compromise 
cerebral perfusion and worsen outcome in the context of carotid stenosis, in a 
secondary analysis of the ENOS trial, GTN appeared safe in both ipsilateral and 
bilateral stenosis. Further, participants with ³70% ipsilateral stenosis who received 
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GTN had a favourable shift in mRS as compared to those randomised to no GTN (OR 
0.56, 95% CI 0.34 to 0.93, p=0.024)[48]. Dehydration is a common finding in 
patients with acute stroke and antihypertensive medication can have accentuated 
effects on BP in such patients. However, in 310 ENOS participants with baseline blood 
markers of dehydration, GTN was safe in those with biomarker evidence of 
dehydration with no precipitous drops in BP [49]. Of note, patients felt to be clinically 
dehydrated were unlikely to have been enrolled into ENOS. Nevertheless, this analysis 
is reassuring and supports the use of GTN prior to blood markers of dehydration being 
available. 
 
3. Transdermal GTN and ultra-acute stroke 
Given the findings from ENOS-early and RIGHT, the Rapid Intervention with Glyceryl 
trinitrate in Hypertensive stroke Trial-2 (RIGHT-2) trial was performed to assess the 
safety and efficacy of transdermal GTN within four hours of stroke onset [50].  
RIGHT-2 was a UK multicentre, paramedic-delivered, ambulance-based, prospective, 
randomised, sham-controlled, blinded-endpoint trial that recruited 1149 participants 
with presumed stroke within 4 hours of onset and systolic BP >120 mmHg; 
participants were randomised to a daily GTN 5mg patch or sham dressing given for 4 
days. Patients were randomised at a median of 71 mins after ictus, and 52% had an 
ischaemic stroke, 13% ICH, 26% stroke mimic and 9% transient ischaemic attack 
(TIA). At hospital admission, GTN lowered BP by 5.8 / 2.6 mmHg as compared with 
sham. Due to the high proportion of patients with a stroke mimic, a hierarchical 
analysis of the primary outcome of mRS at day 90 was planned a priori, first in those 
with a stroke or TIA, and then in the whole population. Although it was feasible for 
paramedics to recruit patients into a UK pre-hospital stroke trial, GTN did not 
influence the primary or secondary clinical outcomes at day 90 in either analysis [50]. 
 
The discrepancy between RIGHT-2 and prior data warrants further discussion. RIGHT-
2 was different in design to ENOS-early recruiting patients much earlier (71 min vs. 
257 min), with different inclusion criteria resulting in a population of older patients 
with more pre-morbid dependency, previous stroke, ischaemic heart disease and 
diabetes. Further, to reduce excess time for paramedics, RIGHT-2 utilised simple 
block randomisation and did not use computer-based minimisation as in ENOS. 
Therefore, there may have been baseline imbalances not apparent with current pre-
hospital scoring systems. This may explain why GTN was associated with improved 
clinical outcomes in those with stroke mimics; a finding which could also represent 
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chance. RIGHT-2 also used a 4-day treatment period whilst previous trials used 7 
days with higher rates of adherence and recruited patients with broader baseline BP 
(systolic BP >120 mmHg in RIGHT-2 vs. 140-220 mmHg in ENOS). 
 
In a RIGHT-2 subgroup analysis of those participants with ICH (n=145), there was a 
tendency towards worse clinical outcome in those randomised to GTN; these 
participants had larger haematoma and more mass effect on admission imaging at a 
median of 2.3 hours after onset and 1.2 hours after treatment. This continued on day 
2 imaging, whereby GTN was associated with larger haematoma and increased 
perihaematomal oedema and midline shift as compared to those randomised to sham. 
Without imaging pre-randomisation, it is difficult to establish whether those 
randomised to GTN had larger haematoma prior to treatment or were more likely to 
undergo haematoma expansion with GTN. In such a small subgroup, these results 
should be regarded as preliminary. Ongoing studies assessing transdermal GTN 
(Multicentre randomised trial of acute stroke treatment in the ambulance with a 
nitroglycerin patch [MR-ASAP]: ISRCTN99503308) and intravenous urapidil (Intensive 
ambulance-delivered blood pressure reduction in hyperacute stroke trial-4 
[INTERACT-4]: NCT03790800) in the pre-hospital arena should shed further light on 
whether using GTN, or BP-lowering therapy more broadly, is safe in ultra-acute ICH. 
 
4. ‘Time is brain’ vs. ‘too early’ 
Taking together all of the data for GTN in acute stroke, it is possible to build a 
potential time-dependent model. Previously, it was proposed that GTN might behave 
in a similar manner to reperfusion treatments such as thrombolysis and 
thrombectomy, i.e. GTN might be effective when given within 6 hours of onset but 
neutral when administered thereafter (Table 2). However, with the addition of RIGHT-
2 into meta-analysis totalling 5005 patients, there now appears to be a U-shaped 
phenomenon whereby ultra-early treatment with GTN in under 2 hours of symptom 
onset is neutral (or even negative), treatment between 2 and 6 hours is beneficial, 
and treatment beyond 6 hours is neutral (Table 3, Figure 1). Overall, the pooled 
treatment effect of GTN is neutral and the time-dependent findings are primarily 
driven by the individual trial results discussed above. 
 
The potential mechanisms driving these time-dependent findings, if real, can be 
postulated. In ICH, transdermal GTN may be harmful when given before hospital in 
the first two hours of symptom onset. Although GTN did not demonstrate antiplatelet 
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effects in the GTN-1 trial, NO has potent antiplatelet properties and GTN may 
therefore inhibit the platelet plugging phase, in addition to the vasoconstrictory phase, 
of haemostasis. When the vasoconstrictory and platelet plugging phases of 
haemostasis are complete (typically before 2 hours), BP lowering with GTN may be 
beneficial when administered between 2-6 hours after onset, perhaps through 
reducing haematoma expansion and perihaematomal oedema and so resulting in 
improved clinical outcomes. In ischaemic stroke patients, BP lowering in the context 
of large vessel occlusion prior to recanalisation may be harmful, reducing regional 
cerebral blood flow, extending the ischaemic core and thus reducing the potentially 
salvageable brain tissue. A subgroup analysis of the enhanced control of hypertension 
and thrombolysis stroke study (ENCHANTED) BP arm alluded to this; hyperacute 
intensive BP lowering of patients with large vessel occlusion undergoing thrombolysis 
was associated with worse clinical outcomes [51]. Further imaging analysis of RIGHT-
2 and MR-ASAP should prove illuminating.  
 
5. Current clinical applications of transdermal GTN in acute stroke 
Given transdermal GTN’s safety profile in hospital-based trials of acute stroke, it 
seems appropriate to consider using this medication in the following scenarios. First, 
systolic BP lowering to <185 mmHg in the context of thrombolysis in acute ischaemic 
stroke. Transdermal GTN may prepare patients for thrombolysis by lowering systolic 
BP below the licensed threshold of 185 mmHg. In RIGHT, there was a non-significant 
increase in both rates of and time to thrombolysis [44]. In the 2016 meta-analysis, 
those with ischaemic stroke who received thrombolysis had a significant shift to better 
functional outcome at day 90 in the presence of GTN [45]. Whether this effect is 
maintained beyond 90 days is unknown. Second, in hypertensive patients at 2-6 
hours of stroke onset. ENOS-early demonstrated that treatment with transdermal GTN 
under 6 hours of onset improved multiple clinical outcomes in both ischaemic and 
haemorrhagic stroke [43]. Given the ease of application (and removal) of a topical 
patch without the need for intravenous access in the setting of dysphagia, 
transdermal GTN is a safe way to initiate BP lowering therapy until such access can be 
obtained. 
 
6. Future clinical applications of transdermal GTN in acute stroke 
The role of transdermal GTN in the setting of thrombectomy is unclear. Further data 
are needed to establish whether waiting until recanalisation has been achieved prior 
to lowering BP is a safer option. Imaging analysis assessing whether GTN influences 
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collaterals – a key determinant of outcome in large vessel occlusion – may provide 
insight into a population of stroke patients that may benefit. Given the subgroup 
analysis of ICH patients from RIGHT-2, transdermal GTN should only be used in the 
pre-hospital setting in the context of a clinical trial (as with MR-ASAP). On-going trials 
will help to understand whether BP lowering in the ambulance is safe in presumed 
stroke patients and to further elucidate the time dependent effects on outcome. The 
data pertaining to transdermal GTN in acute stroke have, thus far, been investigated 
by one group of authors. Importantly, on-going trials are being performed by different 




Transdermal GTN is safe to lower elevated BP beyond two hours of stroke onset and 
may improve outcome when administered within two to six hours, but requires 
confirmation. When treatment is likely to be started within two hours, as in the pre-
hospital setting, transdermal GTN should only be used in research trials whilst its 
safety is further tested in ultra-acute stroke. Future research may help to answer: 
whether to lower elevated BP in those with large vessel occlusion prior to 
thrombectomy; whether to lower elevated BP in ICH patients prior to hospital; and the 
time course of when, and if, to intervene, duration and with which agent. 
 
8. Expert opinion 
Transdermal GTN is an easy to administer BP-lowering therapy which safely reduces 
BP when given after 2 hours of stroke onset, may improve outcome when initiated 
within 2-6 hours, but should be avoided (outside of a clinical trial) in the ultra-acute 
period within 2 hours of stroke onset, particularly when given pre-hospital. Given its 
affordability and ease of application (and removal), transdermal GTN is an ideal agent 
to lower elevated BP in acute stroke patients 2-6 hours after onset. Further research 
needs to investigate the mechanisms of benefit or harm in ultra-acute intracerebral 
haemorrhage, ischaemic stroke or transient ischaemic attack. Such avenues may 
include imaging markers that GTN may influence such as collateral status in patients 
with large vessel occlusion, the timing of BP-lowering therapy in relation to 
mechanical thrombectomy, and the effects on BP variability by different 
antihypertensive agents. GTN may also complement other stroke treatment strategies 
such as anticoagulation reversal in ICH and treatments to reduce brain oedema 
following severe stroke.  
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On-going trials (MR-ASAP: ISRCTN99503308, INTERACT-4: NCT03790800) will help 
to answer whether lowering elevated BP is safe in ultra-acute stroke and ascertain 
whether certain groups of patients benefit whilst others may be harmed. In future, 
lowering of elevated BP in acute stroke may be dependent on stroke severity, stroke 
type, consideration of large vessel occlusion and other imaging markers, as well as 
co-morbidities, frailty and prior antihypertensive treatment. We may be able to target 
certain patient populations in acute stroke who may benefit from BP lowering; 
whether this will be agent-specific (e.g. transdermal GTN) or a more general effect of 
BP lowering, route-specific (intravenous, topical, enteral), time-dependent (early but 
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Table 1. Effects of GTN in stroke patients 
 












n 37 90 18 41 4011 1149 
OTR (hrs) 99.2 55.1 72.2 1.6 26.0 1.2 
Systolic BP (mmHg) ê 13 (7.8%)  ê 23 (14%) ê 21 ê 7 ê 5.8 
Diastolic BP (mmHg) ê 5.2 (5.4%)  ê 4 (3%) ê 6 ê 3.5 ê 2.6 
Heart rate (bpm) No change No change No change No change é 1.4  
MAP (mmHg)  ê 6.2%   ê 4.7  
PP (mmHg)  ê 3.9  ê 16 ê 3.6  
PPI     No change  
RPP (mmHg.bpm)    No change ê 278  
BP variability (SBP SD) No change No change No change ê 7.2 ê 0.4  
Augmentation index  Improved  Improved   
Cerebral blood flow 
velocity 
 No change No change    
Cerebral blood flow   No change    
Zero flow pressure   No change    
Platelet function No change      
BP: blood pressure; bpm: beats per minute; GTN: glyceryl trinitrate; MAP: mean arterial pressure; PP: pulse pressure; PPI: pulse 





Table 2. Comparison of transdermal GTN with other treatments for acute stroke; odds ratio are for a worse outcome (i.e. 
numbers <1 suggest benefit) 
 
Intervention Time window Primary outcome Odds ratio (95% CI) NNT 
Aspirin [53] <48 hrs 
Death or dependency at least 30 days 
after stroke 
0.95 (0.91, 0.99) 79 
Alteplase [54] 0-3 hrs 
mRS 0-1 (functional independence) at 
3-6 months 
0.57 (0.44, 0.74) 10 
 3-4.5 hrs 
mRS 0-1 (functional independence) at 
3-6 months 
0.79 (0.66, 0.95) 19 
Thrombectomy [55] <6 hrs 
Ordinal mRS at 90 days (OR >1 = 
better outcome) 
0.40 (0.28, 0.57) 2.6* 
Transdermal GTN [43] <6 hrs 
Ordinal mRS at 90 days (OR <1 = 
better outcome) 
0.51 (0.32, 0.80) 5.2* 
CI: confidence interval; GTN: glyceryl trinitrate; mRS: modified Rankin Scale; NNT: number needed to treat; OR: odds ratio. 






Table 3. Clinical outcomes with GTN in stroke by onset to randomisation. Data are number, mean difference, or odds ratio with 
95% confidence intervals. Comparisons by binary logistic regression, ordinal logistic regression or multiple linear regression, with 
adjustment. Significant (p<0.05) results in bold. 
  
Onset to randomisation (hours) 
  All ≤ 2 2.1 - 6 6.1 - 12 > 12 
Patients (N) 5005 708 440 439 3418 
Death (%) 0.96 (0.82, 1.12) 1.19 (0.83, 1.72) 0.59 (0.35, 0.99) 1.22 (0.75, 1.98) 0.94 (0.77, 1.14) 
mRS  1.01 (0.91, 1.11) 1.11 (0.84, 1.48) 0.61 (0.43, 0.87) 1.07 (0.77, 1.51) 1.05 (0.93, 1.18) 
Barthel Index 1.31 (-0.42, 3.04) -1.5 (-7.08, 4.07) 7.71 (1.86, 13.56) 0.43 (-5.84, 6.7) 0.95 (-1.02, 2.93) 
TICS-M  -0.07 (-0.74, 0.60) -0.89 (-2.88, 1.11) 1.64 (-0.37, 3.65) 0.07 (-2.2, 2.35) -0.23 (-1.02, 0.57) 
ZDS  0.07 (-1.29, 1.43) -0.89 (-2.88, 1.11) -5.84 (-10.69, -0.99) 0.7 (-3.95, 5.35) 0.47 (-1.10, 2.03) 
HUS 0 (-0.02, 0.02) -0.75 (-2.41, 0.92) 0.04 (-0.03, 0.1) -0.01 (-0.08, 0.05) 0 (-0.02, 0.02) 
EQ-VAS  0.28 (-1.35, 1.9) 1.81 (-2.72, 6.34) 5.23 (-0.41, 10.87) -1.46 (-7.25, 4.34) 0.12 (-1.80, 2.03) 
EQ-VAS: Euro-Quality of life visual analogue scale; HUS: health utility scale (derived from EQ-5D); mRS: modified Rankin Scale; 
TICS-M: telephone interview cognition scale; ZDS: Zung depression scale 
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CI: confidence interval; OR: odds ratio; OTR: onset to randomisation 
 
